COVID-19 Archive:ワクチン｜株式会社Smart119｜新型コロナウィルス感染症関連論文アーカイブ

SARS-CoV-2-Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women (JAMA 2021.4.12)

2021.04.12

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination (NEJM 2021.4.9)

2021.04.06

SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera (Cell 2021.3.20)

2021.03.16

Covid-19 Vaccine Resource Center(NEJM 2021.4.2)②

2021.03.16

Covid-19 Vaccine Resource Center （NEJM 2021.4.2)①

2021.03.05

Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2 (JAMA 2021.3.3)

2021.03.02

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting (NEJM 2021.2.24)

2021.03.02

The Johnson & Johnson Vaccine for COVID-19 (JAMA 2021.3.1)

2021.02.24

How soon will COVID-19 vaccines return life to normal? (Science 2021.2.16)

2021.02.15

Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US--December 14, 2020-January 18, 2021(JAMA 2021.2.12)

2021.02.05

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine (N Eng J Med 2021.2.4)

2020.10.28

What Is Herd Immunity? (JAMA 2020.10.19)

2020.10.02

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults (N Eng J Med 2020.09.29)

2020.09.23

Coronavirus reinfections: three questions scientists are asking (Nature 2020.09.04)

2020.08.17

The Pandemic's Future (Nature 2020.08.06)

2020.07.31

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates (N Eng J Med 2020.07.28)

2020.07.17

The Covid-19 Vaccine-Development Multiverse (N Eng J Med. 2020.07.14)

2020.07.15

An mRNA Vaccine against SARS-CoV-2 -- Preliminary Report (N Eng J Med. 2020.07.14)

2020.05.22

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial (Lancet, 2020.05.22)

COVID-19 Archive: ワクチン

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination (NEJM 2021.4.9)

SARS-CoV-2-Specific Antibodies in Breast Milk After COVID-19 Vaccination of Breastfeeding Women (JAMA 2021.4.12)

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination (NEJM 2021.4.9)

SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera (Cell 2021.3.20)

Covid-19 Vaccine Resource Center(NEJM 2021.4.2)②

Covid-19 Vaccine Resource Center （NEJM 2021.4.2)①

Delayed Large Local Reactions to mRNA-1273 Vaccine against SARS-CoV-2 (JAMA 2021.3.3)

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting (NEJM 2021.2.24)

The Johnson & Johnson Vaccine for COVID-19 (JAMA 2021.3.1)

How soon will COVID-19 vaccines return life to normal? (Science 2021.2.16)

Reports of Anaphylaxis After Receipt of mRNA COVID-19 Vaccines in the US--December 14, 2020-January 18, 2021(JAMA 2021.2.12)

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine (N Eng J Med 2021.2.4)

What Is Herd Immunity? (JAMA 2020.10.19)

Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults (N Eng J Med 2020.09.29)

Coronavirus reinfections: three questions scientists are asking (Nature 2020.09.04)

The Pandemic's Future (Nature 2020.08.06)

Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates (N Eng J Med 2020.07.28)

The Covid-19 Vaccine-Development Multiverse (N Eng J Med. 2020.07.14)

An mRNA Vaccine against SARS-CoV-2 -- Preliminary Report (N Eng J Med. 2020.07.14)

Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial (Lancet, 2020.05.22)